Moleculin Receives Approval for Leukemia Clinical Trial

June 20, 2018 by Website Admin in

Moleculin announced it has received Polish National Office approval to begin its second Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia.

Tweet

Share

Pin it

Previous StoryLivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring Next StoryMoleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market